Molecular Design of Ras Farnesyltransferase Inhibitors
Ras 法尼基转移酶抑制剂的分子设计
基本信息
- 批准号:11694297
- 负责人:
- 金额:$ 5.82万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:1999
- 资助国家:日本
- 起止时间:1999 至 2001
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Oncogene ras is found in many mammalian cancer cells and the encoded protein Ras is an important target for anticancer agents. The farnesylation of the terminal cystein residue of the Ras protein by farnesyltransferase (FTase) is essential for the function of the Ras protein.Considering that the Ras protein is a zinc enzyme, the objective of the present research is to design and synthesize zinc chelating agents to find novel inhibitors of FTase by a collaboration of synthetic organic chemists, FTase enzymologists, and researchers of oncogene and cellular signaling.In 2001 a diversified research was carried out by the participation of US colleagues, Fuyuhiko Tamanoi (University of California, Los Angeles), Terrence R. Burke (National Institute of Health), Patrick J. Casey (Duke University), David R. Corey (University of Texas Southwestern Medical Center at Dallas), John S. Lazo(University of Pittsburgh), Veeraswamy Manne (Bristol-Myers Squibb Pharmaceutical Research Institute) in addition to the Investigators of this project, Otsuka, Okawara, Yamasaki, Okamoto, Umezawa, and Imoto. An international symposium (US-Japan Joint Symposium on Chemistry-Biology Interface) was held in Kumamoto (July 27 and 28, 2001) to report and discuss the research results of the present research project.The results of 2001 were summarized as follows : (i) Farnesyltransferase mutants were inhibited by various synthetic chelators consisting of a dimethylaminopyridine and histamine side chains, (ii) A histidine-pyridine-histidine ligand was found to be a useful as a sensitizer for the hyperthermic treatment of cancer cell lines. (iii) The relationships betweenthe farnesylation of Ras and farnesyltransferase were elucidated, (iv) Clinical application of farnesyltransferase inhibitors was studied, (v) Inhibitors of Grb2SH domain were synthesized.
癌基因ras存在于许多哺乳动物癌细胞中,其编码的蛋白Ras是抗癌药物的重要靶点。Ras蛋白是一种锌酶,因此本研究的目的是设计合成锌螯合剂,寻找新型的法尼基转移酶抑制剂,并将其应用于Ras蛋白的研究中。2001年,美国同行Fuyuhiko Tamanoi(加州大学,洛杉矶)、Terrence R. Burke(国家卫生研究所)、帕特里克J.凯西(杜克大学)、大卫R.科里(德克萨斯大学西南医学中心达拉斯),约翰S。Lazo(匹兹堡大学)、Veeraswamy Manne(百时美施贵宝制药研究所)以及本项目的研究者Otsuka、Okawara、Yamasaki、Okamoto、Umezawa和Imoto。国际研讨会(美日化学生物界面联合研讨会)在熊本召开(2001年7月27日及28日),汇报及讨论本研究计划的研究结果。2001年的研究结果概述如下:(i)法尼基转移酶突变体被由二甲基氨基吡啶和组胺侧链组成的各种合成螯合剂抑制,(ii)发现组氨酸-吡啶-组氨酸配体可用作癌细胞系的热处理的敏化剂。(iii)(iv)法尼基转移酶抑制剂的临床应用研究;(v)Grb 2SH结构域抑制剂的合成。
项目成果
期刊论文数量(17)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Teruhiko Inoue: "Fluorescence property of oxazole yellow-linked oliganucleotide.Triple helix formation and photocleqvage of double-stranded DNA"Bioorg. Med. Chem.. 7. 1207-1211 (1999)
Teruhiko Inoue:“恶唑黄连接寡核苷酸的荧光特性。双链 DNA 的三螺旋形成和光裂解”Bioorg。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Masami Otsuka: "Synthesis, structure of Cu (II) complexes of S-containing pentadentate ligands"J.Organomet.Chem.. 611. 577-585 (2000)
Masami Otsuka:“含S五齿配体的Cu(II)络合物的合成、结构”J.Organomet.Chem.. 611. 577-585 (2000)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hiromasa Kurosaki: "Synthesis, Characterization, and Spectroscopic Properties of Three Novel Pentadentate Copper (II) Complex Related to the Metal-Chelating Inhibitors against the DNA-Binding with HIV-EP1"J. Chem, Soc., Dalton. 2001. 441-447 (2001)
Hiromasa Kurosaki:“与抗 HIV-EP1 DNA 结合的金属螯合抑制剂相关的三种新型五齿铜 (II) 配合物的合成、表征和光谱特性”J.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hiromasa Kurosaki: "Synthesis, Characterization, and Spectroscopic Properties of Three Novel Pentadentate Copper(II) Complex Related to the Metal-Chelating Inhibitors against the DNA-Binding with HIV-EP1"J.Chem.Soc., Dalton Trans.. 2001. 441-447 (2001)
Hiromasa Kurosaki:“与抗 HIV-EP1 DNA 结合的金属螯合抑制剂相关的三种新型五齿铜 (II) 配合物的合成、表征和光谱特性”J.Chem.Soc.,Dalton Trans.. 2001。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yasuharu Hori: "Sensitizaiton of Hyperthermic Treatment of Leukemic Cell Lines by a Synthetic Peptide"Bioorg. Med. Chem.. 10(1). 111-115 (2002)
Yasuharu Hori:“合成肽对白血病细胞系热疗的敏感性”Bioorg。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OTSUKA Masami其他文献
OTSUKA Masami的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OTSUKA Masami', 18)}}的其他基金
Design and synthesis of anti-brain tumor and brain-protective drugs using brain-targeting peptides
脑靶向肽设计与合成抗脑肿瘤和脑保护药物
- 批准号:
24659048 - 财政年份:2012
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of medicinal molecules having biologically functions targeting the PI3K/Akt pathway and the TGF-b/Smad pathway
开发具有针对PI3K/Akt途径和TGF-b/Smad途径的生物学功能的药物分子
- 批准号:
23390028 - 财政年份:2011
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Design and synthesis of anti-HIV agents that inhibit the Vif-mediated proteasome degradation of APOBEC3G
设计和合成抑制 Vif 介导的 APOBEC3G 蛋白酶体降解的抗 HIV 药物
- 批准号:
22659024 - 财政年份:2010
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Design of DNA-cleaving and -crosslinking agents based on NFκB and HMGA proteins aiming at the application to cancer therapy
基于 NFκB 和 HMGA 的 DNA 切割和交联剂设计,针对蛋白质在癌症治疗中的应用
- 批准号:
20390033 - 财政年份:2008
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of zinc chelators with protein specificity aiming at molecular target therapy of cancer
开发针对癌症分子靶向治疗的蛋白质特异性锌螯合剂
- 批准号:
17390030 - 财政年份:2005
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular design of anti-AIDS drugs targeting the viral and host zinc proteins
针对病毒和宿主锌蛋白的抗艾滋病药物的分子设计
- 批准号:
15390038 - 财政年份:2003
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular design of anti-AIDS drugs targeting the human transcription machinery employed for the replication of AIDS virus
针对艾滋病病毒复制所用的人类转录机制的抗艾滋病药物的分子设计
- 批准号:
12557219 - 财政年份:2000
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of compounds for multiple regulation of intracellular signaling
开发用于细胞内信号传导多重调节的化合物
- 批准号:
11470496 - 财政年份:1999
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Molecular design and synthesis of anti-cancer compounds that cause apoptosis
引起细胞凋亡的抗癌化合物的分子设计和合成
- 批准号:
09672280 - 财政年份:1997
- 资助金额:
$ 5.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Disruption of AKT Pathway for Cancer Intervention
破坏 AKT 通路以干预癌症
- 批准号:
7535139 - 财政年份:2004
- 资助金额:
$ 5.82万 - 项目类别:
Disruption of AKT Pathway for Cancer Intervention
破坏 AKT 通路以干预癌症
- 批准号:
7426857 - 财政年份:2004
- 资助金额:
$ 5.82万 - 项目类别:
Eastern Cooperative Oncology Group Chair's Office
东部肿瘤合作组主席办公室
- 批准号:
7262496 - 财政年份:1999
- 资助金额:
$ 5.82万 - 项目类别: